» Articles » PMID: 36875654

From Attention-deficit Hyperactivity Disorder to Sporadic Alzheimer's Disease-Wnt/mTOR Pathways Hypothesis

Overview
Journal Front Neurosci
Date 2023 Mar 6
PMID 36875654
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is the most common neurodegenerative disorder with the majority of patients classified as sporadic AD (sAD), in which etiopathogenesis remains unresolved. Though sAD is argued to be a polygenic disorder, apolipoprotein E (APOE) ε4, was found three decades ago to pose the strongest genetic risk for sAD. Currently, the only clinically approved disease-modifying drugs for AD are aducanumab (Aduhelm) and lecanemab (Leqembi). All other AD treatment options are purely symptomatic with modest benefits. Similarly, attention-deficit hyperactivity disorder (ADHD), is one of the most common neurodevelopmental mental disorders in children and adolescents, acknowledged to persist in adulthood in over 60% of the patients. Moreover, for ADHD whose etiopathogenesis is not completely understood, a large proportion of patients respond well to treatment (first-line psychostimulants, e.g., methylphenidate/MPH), however, no disease-modifying therapy exists. Interestingly, cognitive impairments, executive, and memory deficits seem to be common in ADHD, but also in early stages of mild cognitive impairment (MCI), and dementia, including sAD. Therefore, one of many hypotheses is that ADHD and sAD might have similar origins or that they intercalate with one another, as shown recently that ADHD may be considered a risk factor for sAD. Intriguingly, several overlaps have been shown between the two disorders, e.g., inflammatory activation, oxidative stress, glucose and insulin pathways, wingless-INT/mammalian target of rapamycin (Wnt/mTOR) signaling, and altered lipid metabolism. Indeed, Wnt/mTOR activities were found to be modified by MPH in several ADHD studies. Wnt/mTOR was also found to play a role in sAD and in animal models of the disorder. Moreover, MPH treatment in the MCI phase was shown to be successful for apathy including some improvement in cognition, according to a recent meta-analysis. In several AD animal models, ADHD-like behavioral phenotypes have been observed indicating a possible interconnection between ADHD and AD. In this concept paper, we will discuss the various evidence in human and animal models supporting the hypothesis in which ADHD might increase the risk for sAD, with common involvement of the Wnt/mTOR-pathway leading to lifespan alteration at the neuronal levels.

Citing Articles

Metabolic Dysfunction in Parkinson's Disease: Unraveling the Glucose-Lipid Connection.

Sian-Hulsmann J, Riederer P, Michel T Biomedicines. 2025; 12(12.

PMID: 39767747 PMC: 11673947. DOI: 10.3390/biomedicines12122841.


Unlocking Hope: Therapeutic Advances and Approaches in Modulating the Wnt Pathway for Neurodegenerative Diseases.

Faraji N, Ebadpour N, Abavisani M, Gorji A Mol Neurobiol. 2024; 62(3):3630-3652.

PMID: 39313658 PMC: 11790780. DOI: 10.1007/s12035-024-04462-4.


Psychiatric Disease as a Potential Risk Factor for Dementia: A Narrative Review.

Hedges D, Chase M, Farrer T, Gale S Brain Sci. 2024; 14(7).

PMID: 39061462 PMC: 11274614. DOI: 10.3390/brainsci14070722.


Diet-induced hyperhomocysteinemia causes sex-dependent deficiencies in offspring musculature and brain function.

Suszynska-Zajczyk J, Witucki L, Perla-Kajan J, Jakubowski H Front Cell Dev Biol. 2024; 12:1322844.

PMID: 38559811 PMC: 10979824. DOI: 10.3389/fcell.2024.1322844.


Insights into Gastrointestinal Redox Dysregulation in a Rat Model of Alzheimer's Disease and the Assessment of the Protective Potential of D-Galactose.

Homolak J, Varvaras K, Sciacca V, Babic Perhoc A, Virag D, Knezovic A ACS Omega. 2024; 9(10):11288-11304.

PMID: 38496956 PMC: 10938400. DOI: 10.1021/acsomega.3c07152.


References
1.
Bellenguez C, Kucukali F, Jansen I, Kleineidam L, Moreno-Grau S, Amin N . New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet. 2022; 54(4):412-436. PMC: 9005347. DOI: 10.1038/s41588-022-01024-z. View

2.
Llorens-Martin M, Jurado J, Hernandez F, Avila J . GSK-3β, a pivotal kinase in Alzheimer disease. Front Mol Neurosci. 2014; 7:46. PMC: 4033045. DOI: 10.3389/fnmol.2014.00046. View

3.
Perluigi M, Di Domenico F, Barone E, Butterfield D . mTOR in Alzheimer disease and its earlier stages: Links to oxidative damage in the progression of this dementing disorder. Free Radic Biol Med. 2021; 169:382-396. PMC: 8145782. DOI: 10.1016/j.freeradbiomed.2021.04.025. View

4.
Tian S, Tan S, Jia W, Zhao J, Sun X . Activation of Wnt/β-catenin signaling restores insulin sensitivity in insulin resistant neurons through transcriptional regulation of IRS-1. J Neurochem. 2020; 157(3):467-478. DOI: 10.1111/jnc.15277. View

5.
Abu-Elfotuh K, Abdel-Sattar S, Abbas A, Mahran Y, Alshanwani A, Hamdan A . The protective effect of thymoquinone or/and thymol against monosodium glutamate-induced attention-deficit/hyperactivity disorder (ADHD)-like behavior in rats: Modulation of Nrf2/HO-1, TLR4/NF-κB/NLRP3/caspase-1 and Wnt/β-Catenin signaling pathways.... Biomed Pharmacother. 2022; 155:113799. DOI: 10.1016/j.biopha.2022.113799. View